Your Sleep Duration May Be More Closely Linked to Alzheimer’s Than You Think, Study Finds

Most adults assume more sleep is better for the brain. Researchers studying 2,410 older adults found the opposite – at least when it comes to one of the most clinically significant proteins in Alzheimer’s disease research.

The protein is called phosphorylated tau 181. It’s not a new discovery, but the question of what drives its accumulation in the bloodstream is one that scientists have been working to answer for years. The new data adds a variable most people wouldn’t think to suspect: how long, on average, someone sleeps each night.

The study draws from one of the longest-running and most respected cohorts in medical research. Its findings don’t tell people to sleep less. They do suggest that habitually long sleep could be worth paying closer attention to – and that the assumption that more rest always means more protection for the aging brain deserves serious reconsideration.

What the Framingham Heart Study Found About Sleep and Alzheimer’s

Regularly sleeping long hours each night is associated with higher levels of an Alzheimer’s-related protein in the blood, even accounting for other health factors, according to a new study from UT Health San Antonio. Modeling across a sample of 2,410 study participants found a link between sleep duration and phosphorylated tau 181, or p-tau181, a modified form of tau protein that is a hallmark of Alzheimer’s disease, and is now detectable in blood.

The study, published May 19, 2026, in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, drew from participants enrolled in the Framingham Heart Study. The sample had a mean age of 70 years, with 55.2% of participants being female. The Framingham Heart Study began in 1948 under the direction of the National Heart, Lung, and Blood Institute and has provided longitudinal health data on generations of participants in Framingham, Massachusetts.

The research was led by Vanessa M. Young, PhD, MS, a postdoctoral research fellow at the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio. Young stated: “Because this is a snapshot in time rather than a long-term study, we cannot say that long sleep causes Alzheimer’s, but the findings suggest it may be worth monitoring, and that more sleep is not always better for brain health.”

Young is a graduate of the Translational Science PhD Program in the Graduate School of Biomedical Sciences at UT Health San Antonio, and conducted the research under the mentorship of founding Biggs Institute director Sudha Seshadri, MD. The Glenn Biggs Institute holds designation as a National Institute on Aging-designated Alzheimer’s Disease Research Center, one of only a select number of federally recognized centers focused on Alzheimer’s research in the country.

The Non-Linear Signal That Linear Analysis Would Have Missed

One of the most technically important aspects of the study is how the association was found. The researchers used a statistical technique called restricted cubic splines – a non-linear modeling approach that maps how a relationship between two variables curves and shifts across a range of values, rather than assuming it moves in a straight line – rather than a standard linear analysis. The restricted cubic spline analysis revealed a robust non-linear association between self-reported sleep duration and plasma p-tau181. P-tau181 levels began accumulating noticeably once regular sleep durations reached 8.5 to 9 hours per night, with the curve rising sharply beyond the 10-hour threshold. Notably, when the researchers used standard categorical cutoffs, no association appeared in adjusted models – which shows that conventional analytical methods would have missed this signal entirely.

The association increased most sharply beyond 10 hours of sleep, suggesting that long sleep might reflect early neurodegenerative processes.

The non-linear association held after adjusting for factors including age, sex, sleep apnea, depression, kidney function, and apolipoprotein E ε4 (APOE ε4) genotype. APOE ε4 is the strongest genetic risk factor for late-onset Alzheimer’s disease – controlling for it makes the persistence of the sleep-p-tau181 association considerably more meaningful.

Why P-tau181 Matters as a Biomarker

Phosphorylated tau 181 is a modified form of tau protein that is a hallmark of Alzheimer’s disease, and is now detectable in blood. This last point – detectable in blood – represents a significant shift in how early Alzheimer’s pathology can be identified. For most of modern medicine’s history, confirming the presence of tau pathology in a living patient required either a spinal tap (cerebrospinal fluid analysis) or a specialized PET scan, both expensive and inaccessible for most people.

Current treatments for Alzheimer’s are most effective in the disease’s earliest stages, making the development of reliable, non-invasive biomarkers for early diagnosis a clinical priority. Abnormal tau protein aggregation is a key pathological hallmark of Alzheimer’s disease, disrupting neuronal integrity and associating closely with cognitive decline. Tau pathology has traditionally been evaluated mainly by cerebrospinal fluid analysis and tau PET, which are invasive or costly and limit their clinical applicability.

Plasma p-tau181 could not only serve as a reliable biomarker for diagnosing Alzheimer’s disease progression, but could also identify those at risk of converting to AD dementia and worsening cognition since the earliest stage of the disease. A 2025 study led by Giulia Giacomucci at the University of Florence’s Department of Neuroscience, Psychology, Drug Research and Child Health, published in Annals of Clinical and Translational Neurology, enrolled 163 participants across the Alzheimer’s spectrum and found that plasma p-tau181 successfully identified patients at risk of converting to full Alzheimer’s dementia over time.

Research published in 2025 found that changes in blood p-tau181 levels occur before the appearance of positive amyloid PET results – the brain imaging technique used to confirm amyloid plaques, which are the other core pathological feature of Alzheimer’s disease. In other words, elevated p-tau181 in blood can signal biological processes underway before conventional brain scans would detect them.

For those who want a broader look at how sleep habits interact with brain aging more generally, this Hearty Soul report on sleep behaviors and white matter lesions covers three specific patterns that have now been linked to structural brain changes visible on MRI, including the risks of sleeping outside the recommended seven-to-nine-hour range.

A Broader Pattern in the Sleep-Dementia Literature

The new study from UT Health San Antonio doesn’t stand alone. A growing body of research links prolonged sleep duration – not just short sleep – to elevated dementia risk, though the mechanisms remain debated.

A 2024 study found that long sleep duration of more than 8 hours was associated with a 64% increased risk of incident dementia.

A 2025 meta-analysis published in The Journals of Gerontology: Series A, which synthesized 15 longitudinal studies involving more than 65,000 participants, found that excessive daytime sleepiness was associated with a 68% increased risk of all-cause dementia, while long sleep duration increased the risk of all-cause dementia by 29%.

A separate systematic review and meta-analysis published in the Journal of Neurology found that long sleep duration – defined as more than 8 hours – carried a relative risk of 1.66 for Alzheimer’s disease specifically, alongside elevated risks for cognitive decline and all-cause dementia.

None of these studies, including the new UT Health San Antonio research, establish that long sleep causes Alzheimer’s disease. The direction of causality is a critical open question. Researchers increasingly consider the possibility that extended sleep duration in older adults is a consequence of early, subclinical neurodegeneration rather than its cause – a signal the brain is already changing before any clinical symptoms are noticed.

The Scale of the Alzheimer’s Problem

Understanding why findings like these carry urgency requires some context on the scale of Alzheimer’s disease in the United States. According to 2026 data from the Alzheimer’s Association, an estimated 7.4 million Americans age 65 and older are living with Alzheimer’s disease, representing approximately 1 in 9 people in that age group, or 11% of the population over 65. Between 2000 and 2024, the number of deaths due to Alzheimer’s disease in the U.S. more than doubled, increasing by 134%. Health and long-term care costs for people living with dementia are projected to reach $409 billion in 2026.

Almost two-thirds of Americans with Alzheimer’s are women – a disparity that makes the Framingham Heart Study’s 55.2% female cohort especially relevant to the population most at risk.

What Researchers Don’t Yet Know

The study has clear and acknowledged limitations that are important to understand before drawing conclusions.

Because this was a snapshot in time – a cross-sectional study – rather than a long-term longitudinal design, it is not possible to say that long sleep causes Alzheimer’s disease. The study captured sleep duration and p-tau181 levels at a single point in time for each participant, which means it cannot show whether changes in sleep preceded changes in the protein, or the reverse.

Sleep duration was also self-reported, which introduces the possibility of measurement error. People often misjudge their actual sleep time, and self-reported duration doesn’t account for sleep quality, nighttime wakefulness, or the difference between time spent in bed and time actually asleep.

The study also measured p-tau181, not a clinical Alzheimer’s diagnosis. Elevated p-tau181 is a biomarker of Alzheimer’s pathology – it indicates the presence of a biological process associated with the disease – but it is not equivalent to a diagnosis. Many people with elevated p-tau181 may never develop clinical dementia.

What the researchers are calling for is longitudinal work: studies that follow the same participants across years or decades to determine whether sleep patterns in midlife or early old age predict p-tau181 accumulation over time, and whether that accumulation tracks with cognitive outcomes. That kind of data would allow researchers to say something meaningful about causation rather than correlation.

Key Takeaways

The core finding from the 2026 UT Health San Antonio study is precise: habitually sleeping 8.5 to 9 hours or more per night was associated with higher blood levels of p-tau181, an Alzheimer’s-related protein, in a well-characterized cohort of 2,410 older adults. The association grew sharper beyond 10 hours and held after controlling for sleep apnea, depression, APOE ε4 status, and several other confounders.

This doesn’t mean anyone sleeping 9 hours should panic. Sleep needs are individual, and a single biomarker association from a cross-sectional study is not a clinical verdict. Older adults naturally experience changes in sleep architecture – the internal structure of sleep cycles – that can affect how long they need to spend in bed to feel rested.

What the data does suggest is that consistently long sleep in older adults is worth discussing with a physician, particularly if it represents a change from prior patterns. A shift toward longer sleep, especially when accompanied by excessive daytime fatigue, may in some cases reflect early neurological changes rather than simple lifestyle preference. Blood-based biomarker testing for p-tau181, now increasingly available in clinical settings, offers one way to investigate further.

For the broader public, the clearest takeaway from years of sleep-dementia research – including this study – is that both extremes of the duration spectrum carry risk. The standard recommendation of seven to nine hours per night for adults isn’t arbitrary. It reflects a range within which multiple lines of evidence consistently show the lowest association with adverse cognitive outcomes. Spending substantially more time asleep than that, consistently, is worth paying attention to in the same way that chronic short sleep has been for years.

Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.

Read More: Two Alzheimer’s Drugs Are Now Being Tested to Prevent Dementia Before It Starts